Throughout the last three months, 17 analysts have evaluated Sage Therapeutics (NASDAQ:SAGE), offering a diverse set of opinions from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 3 | 11 | 1 | 1 |
| Last 30D | 0 | 0 | 1 | 0 | 1 |
| 1M Ago | 0 | 1 | 0 | 0 | 0 |
| 2M Ago | 1 | 1 | 9 | 1 | 0 |
| 3M Ago | 0 | 1 | 1 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $19.76, a high estimate of $29.00, and a low estimate of $8.00. Experiencing a 23.77% decline, the current average is now lower than the previous average price target of $25.92.
Investigating Analyst Ratings: An Elaborate Study
The perception of Sage Therapeutics by financial experts is analyzed...
ログインすると全部閲覧できます。
ログイン
